RxDoctor Payments Data

Alfredo Fernandez, MD

General Practice · Tampa, FLNPI 1912252107

Payments from drug & device makers

$426,664in general payments, 2019–2025

Across 172 payments — averaging $2480.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$416K
  • Teva Pharmaceuticals USA, Inc.$5K
  • Kowa Research Institute, Inc.$2K
  • AstraZeneca$971
  • Bayer$888
  • GSK$735
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$4,339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426,664 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$12,760
Medicare patients
23
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban41$26,442
EliquisApixaban30$21,070
EntrestoSacubitril/Valsartan18$16,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,465
MyrbetriqMirabegron14$11,669
JardianceEmpagliflozin11$8,286
SymbicortBudesonide/Formoterol Fumarate29$8,028
Megestrol Acetate19$2,859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,655
Ventolin HfaAlbuterol Sulfate25$1,484
Ezetimibe22$1,445
Albuterol Sulfate HfaAlbuterol Sulfate46$1,144
Diclofenac Sodium30$1,007
Latanoprost12$980
Fluticasone Propionate68$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$375$26,44241 claims
NovartisEntresto$322$16,47518 claims
GSKTrelegy Ellipta$735$13,46521 claims
Boehringer IngelheimJardiance$148$8,28611 claims
AstraZenecaSymbicort$971$8,02829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →